Investors insist halted biotech IPOs will return in 2025
The slowdown in IPOs following tariff-associated turbulence and FDA reorganisation will soon pass, say industry investors.
IPO Industry
Aardvark prices $94.2m IPO to fund development of Prader-Willi syndrome drug
Ascentage Pharma raises $126m in first biotech IPO of 2025
Bicara Therapeutics closes $362m IPO in flurry of biotech listing activity
Global stock market crash likely to delay biotech IPOs
Money moves: How the biotech market is weathering inflationary storms
Valneva receives up to £20m vaccine R&D funding in Scotland
Covid-19 update: Yellen calls for new fund to tackle future health crises
